Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
OCULAR THERAPEUTIX, INC (OCUL) reported that its Chief Operating Officer, Donald Notman, sold 1,099 shares of common stock on August 31, 2026, at a weighted average price of $10.24 per share in an open-market transaction. The sale was executed under a durable automatic sale instruction to satisfy tax withholding from restricted stock units vesting on August 29, 2026, and is described as non-discretionary. Following this transaction, Notman held 366,529 shares directly, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
OCULAR THERAPEUTIX, INC (OCUL) has a notice of proposed sale of common stock filed under Rule 144 on behalf of Donald D. Notman Jr. The filing covers 1,099 shares of common stock, described as restricted stock vesting under a registered plan, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. The reported transaction date is August 31, 2026, with an indicated total value of $11,251.89.
OCULAR THERAPEUTIX, INC (OCUL) officer Peter Kaiser, Chief Development Officer, reported a sale of 3,035 shares of common stock on August 24, 2026, at a weighted average price of $10.77 per share. The transaction was executed under a pre-arranged durable automatic sale instruction to cover tax withholding on restricted stock units vesting on August 22, 2026, and is described as non-discretionary. After this sale, Kaiser directly holds 264,378 shares, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
OCULAR THERAPEUTIX, INC (OCUL) insider Sanjay Nayak, Chief Strategy Officer, reported a sale of 1,897 shares of Common Stock on 2026-08-24 at a weighted average price of $10.78 per share. The shares were sold pursuant to a durable automatic Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding on RSUs vesting on 2026-08-22 and are described as non-discretionary. Following this transaction, Nayak directly holds 326,898 shares of OCUL common stock.
OCULAR THERAPEUTIX, INC (OCUL) reported that Chief Scientific Officer Jeffrey S. Heier sold 3,296 shares of common stock on August 24, 2026 at a weighted average price of $10.78 per share. The sale was made under a durable automatic sale instruction adopted on April 9, 2024 to effect a sell-to-cover election for tax withholding on restricted stock units vesting on August 22, 2026, and is described as non-discretionary. Following this transaction, Heier beneficially owns 318,326 shares, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
OCULAR THERAPEUTIX, INC (OCUL) reported insider activity by Executive Chairman, President and CEO Pravin Dugel. On August 24, 2026, he sold 21,649 shares of common stock at a weighted average price of $10.77 per share in open-market transactions, pursuant to a durable automatic Rule 10b5-1 sale instruction adopted on February 21, 2024, to satisfy tax withholding obligations related to restricted stock units vesting on August 22, 2026. Following this sale, he directly held 2,525,429 common shares. On August 25, 2026, his spouse transferred 50,092 shares as a bona fide gift to the Pravin Dugel 2024 Irrevocable Trust for no consideration; Dugel is trustee and lifetime sole beneficiary, and remains the beneficial owner. As a result, indirect holdings shifted from 50,092 shares held by spouse to 744,903 shares held through the trust.
OCULAR THERAPEUTIX, INC. (symbol OCUL) received a notice under Rule 144 that officer Sanjay Nayak intends to sell up to 1,897 shares of common stock. The shares relate to restricted stock vesting under a registered plan, with sales to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also reports that during the prior three months, Sanjay Nayak sold 1,858 shares of OCUL common stock on 05/26/2026 for $15,236.53.
OCULAR THERAPEUTIX, INC. (OCUL) received a Notice of Proposed Sale of Securities on Form 144 filed for officer Pravin Dugel. The notice covers a proposed sale of 21,649 shares of common stock, relating to restricted stock scheduled to vest on August 22, 2026, to be sold through Morgan Stanley Smith Barney LLC. The filing also reports that Dugel sold 21,156 shares of common stock during the prior three months for aggregate proceeds of $173,513.05.
OCULAR THERAPEUTIX, INC. (OCUL) is the issuer of common stock that Jeffrey S. Heier plans to sell under Rule 144. A notice covers a proposed sale of 3,296 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $35,532.20, tied to restricted stock vesting under a registered plan. The filing also reports that Heier sold 3,018 common shares over the prior three months for $24,745.19.
OCULAR THERAPEUTIX, INC. (OCUL) received a Rule 144 notice from officer Peter Kazuo Kaiser covering a planned sale of company common stock. The notice lists 3,035 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated aggregate value of $32,701.82. The shares relate to restricted stock vesting under a registered plan, with vesting and proposed sale timing noted in August 2026. The filing also reports that over the prior three months, Peter Kazuo Kaiser sold 2,967 shares of OCUL common stock for total proceeds of $24,333.55.